RSL3: Glutathione Peroxidase 4 Inhibitor for Ferroptosis in Cancer Research

Executive Summary: RSL3 is a selective inhibitor of glutathione peroxidase 4 (GPX4), a key regulator of lipid peroxidation and oxidative stress in mammalian cells (APExBIO). By blocking GPX4, RSL3 induces ferroptosis, a distinct, iron-dependent form of cell death important in cancer biology (Yang et al., 2021). RSL3 exhibits synthetic lethality with oncogenic RAS mutations, efficiently inhibiting tumorigenic cell growth at nanomolar concentrations. The compound is water-insoluble, DMSO-soluble, and active in both in vitro and in vivo models (Product page). Its specificity and potency make RSL3 an essential tool for ferroptosis research and redox-targeted cancer therapeutic strategies.

Biological Rationale

Ferroptosis is a regulated, non-apoptotic form of cell death characterized by iron-dependent lipid peroxidation and distinct from apoptosis, necrosis, and autophagy (Yang et al., 2021). GPX4 is the central enzyme that reduces lipid hydroperoxides to non-toxic lipid alcohols, thus preventing ferroptosis under physiological conditions. Tumor cells, especially those harboring oncogenic RAS mutations, often exhibit redox vulnerabilities and altered lipid metabolism, making them susceptible to ferroptosis-inducing agents. Lipoxygenases (LOXs) and oxylipin signaling are also implicated in cancer progression and ferroptosis regulation. The downregulation of ALOXE3 in glioblastoma confers resistance to ferroptosis, highlighting the therapeutic potential of targeting ferroptosis pathways (Yang et al., 2021).

Mechanism of Action of RSL3 (glutathione peroxidase 4 inhibitor)

RSL3 binds covalently to the selenocysteine residue in the active site of GPX4, irreversibly inhibiting its peroxidase activity (APExBIO). This inhibition prevents the reduction of phospholipid hydroperoxides to alcohols, leading to the accumulation of lipid peroxides and subsequent ferroptosis. Unlike apoptosis, RSL3-induced cell death is caspase-independent but fully dependent on iron and reactive oxygen species (ROS) accumulation. RSL3 activity can be counteracted by overexpression of GPX4, iron chelators (e.g., deferoxamine), or lipophilic antioxidants (e.g., ferrostatin-1). The specificity of RSL3 for GPX4 over other antioxidant enzymes enables precise dissection of ferroptosis in cellular and animal models (see related review — this article extends by emphasizing translational benchmarks in RAS-driven cancer models).

Evidence & Benchmarks

• RSL3 induces ferroptosis in RAS-driven tumorigenic cells at concentrations as low as 5–10 nM in vitro (Yang et al., 2021, DOI).
• Subcutaneous administration of RSL3 at doses up to 400 mg/kg reduces tumor volume in athymic nude mice xenografted with BJeLR cells, with no observable toxicity (APExBIO).
• RSL3-mediated cell death is independent of caspase activation and can be rescued by GPX4 overexpression or iron chelation (Yang et al., 2021, DOI).
• In glioblastoma models, ALOXE3 deficiency confers resistance to p53-SLC7A11-dependent ferroptosis, underscoring the pathway specificity for RSL3 (DOI).
• RSL3 is insoluble in water and ethanol, but soluble in DMSO at ≥125.4 mg/mL, facilitating high-concentration stock solutions for cell-based assays (APExBIO).

Applications, Limits & Misconceptions

RSL3 is widely applied in cancer biology to induce ferroptosis in vitro and in vivo, particularly in models with redox or lipid metabolism vulnerabilities. Its synthetic lethality with RAS mutations enables exploration of targeted therapies in otherwise resistant tumor types (review — this article updates clinical translation and workflow considerations).

Beyond oncology, RSL3 is used to study oxidative stress, lipid peroxidation, and ferroptosis signaling in neurodegeneration and metabolic diseases. However, results in non-cancer models require careful interpretation due to cell-type-specific redox pathways.

Common Pitfalls or Misconceptions

• RSL3 does NOT induce ferroptosis in cells lacking functional iron metabolism: Iron chelators or iron-deficient conditions block RSL3 efficacy.
• Not effective in apoptosis-centric models: RSL3-induced death is caspase-independent and may not substitute for pro-apoptotic agents.
• Solubility limitations: RSL3 is insoluble in water and ethanol; improper dissolution can cause precipitation and experimental artifacts.
• GPX4 overexpression or lipophilic antioxidants abrogate RSL3 activity: These must be controlled for in rescue experiments.
• Species and cell-type specificity: Non-mammalian or GPX4-deficient models may not respond to RSL3.

Workflow Integration & Parameters

RSL3 (B6095) from APExBIO is supplied as a solid and should be stored at -20°C. Prepare fresh DMSO stock solutions (≥125.4 mg/mL) prior to use, employing warming and sonication to aid dissolution (product details). For in vitro assays, dilute stock into cell culture media to working concentrations (typically 10–500 nM) immediately before use. In vivo, RSL3 is administered subcutaneously or intraperitoneally at dosages up to 400 mg/kg; vehicle and toxicity controls are essential. Solution stability is limited; avoid repeated freeze-thaw cycles. For detailed experimental protocols and troubleshooting, see this protocol guide — this dossier clarifies dose-response and redox rescue strategies beyond standard protocols.

Conclusion & Outlook

RSL3 is a benchmark compound for dissecting ferroptosis, oxidative stress, and redox vulnerabilities in cancer and cell biology. Its selectivity and preclinical efficacy underpin translational strategies for targeting RAS-driven and redox-compromised tumors. Continued research is expanding RSL3's utility in understanding non-apoptotic cell death mechanisms and developing targeted therapeutics. For product specifications and ordering, refer to RSL3 (glutathione peroxidase 4 inhibitor) at APExBIO.